Overview
My long-term goal is to develop new therapies to treat patients with gastrointestinal and other solid tumors. To accomplish this, I am active in designing, writing, and running phase I and II clinical trials. I am also interested in the correlative science that furthers our understanding of cancer at a molecular level. I am interested in the identification of biomarkers, which are characteristics of a given patient's tumor that may help us to understand his or her prognosis or how well he or she may respond to a given therapy. The overall objective of this research is to use the knowledge gained to personalize care and find the very best therapies that will enable our patients to fight their cancer.
Current Appointments & Affiliations
Associate Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2017 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies.
Journal Article ESMO Open · July 2024 BACKGROUND: Pemigatinib is an oral, potent, selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor. FIGHT-101, a three-part, open-label, first-in-human, phase I/II study (NCT02393248), evaluated pemigatinib in patients with advanced solid tumors. ... Full text Link to item CiteCorrection: Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Journal Article Cancer Res Commun · March 13, 2024 Full text Link to item CiteTABLE 3 from Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study
Other · March 12, 2024 <p>Tumor response by RECIST (full analysis set)</p> ... Full text CiteRecent Grants
An open-label, Phase 1a/1b, dose escalation and dose expansion study investigating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of PHST001 in adult patients with advanced relapsed and/or refractory solid tumors
Clinical TrialPrincipal Investigator · Awarded by Pheast Therapeutics, Inc. · 2025 - 2030A PHASE 1 OPEN-LABEL STUDY OF PF-07934040 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS HARBORING MUTATIONS IN THE KRAS GENE
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2025 - 2030A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Clinical TrialPrincipal Investigator · Awarded by PMV Pharmaceuticals, Inc. · 2025 - 2030View All Grants
Education, Training & Certifications
Duke University, School of Medicine ·
2008
M.D.
Duke University ·
2007
Ph.D.